Literature DB >> 10088781

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.

M C Levesque1, F E Ward, D R Jeffery, J B Weinberg.   

Abstract

Human interferon-alpha (IFNalpha) and IFNbeta are administered for treatment of several diseases, including viral infections, malignancies, and multiple sclerosis (MS). IFNalpha therapy has been associated with the production of autoantibodies and the development of a variety of autoimmune disorders, including polyarthritis. This report describes the development of seronegative, symmetric polyarthritis in a patient with relapsing-remitting MS, after 8 weeks of therapy with IFNbeta1a. HLA phenotyping analysis of the patient revealed the presence of HLA-DRB1*0404, an allele known to be associated with the development of rheumatoid arthritis. Therefore, IFNbeta1a may have induced arthritis in a patient who was genetically predisposed to develop arthritis on the basis of HLA determinants. The English-language literature regarding IFNalpha- and IFNbeta-induced polyarthritis is reviewed, and possible mechanisms for IFNalpha- and IFNbeta-induced autoimmunity, including the contribution of HLA determinants and nitric oxide overproduction, are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088781     DOI: 10.1002/1529-0131(199904)42:3<569::AID-ANR23>3.0.CO;2-M

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with IFN-beta.

Authors:  Anne-Christine Karow; Jürgen Braun; Peter Marx; Martin Stangel
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

Review 2.  Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.

Authors:  M Abu-Shakra; D Buskila; M Ehrenfeld; K Conrad; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 3.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 4.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

Review 5.  Rheumatic manifestations of hepatitis C infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

6.  Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.

Authors:  M Corr; D L Boyle; L Ronacher; N Flores; G S Firestein
Journal:  Ann Rheum Dis       Date:  2008-07-24       Impact factor: 19.103

Review 7.  Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation.

Authors:  J B Weinberg
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

Review 8.  Interferon-beta for treatment of rheumatoid arthritis?

Authors:  Judith van Holten; Christine Plater-Zyberk; Paul P Tak
Journal:  Arthritis Res       Date:  2002-09-18

9.  Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphy.

Authors:  Seval Erhamamcı; Bahriye Horasanlı; Ayşe Aktaş
Journal:  Mol Imaging Radionucl Ther       Date:  2014-06-05

Review 10.  Safety, Tolerability, and Immunogenicity of Interferons.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.